Zoledronic acid: past, present and future roles in cancer treatment (Q36429414)

14 August 2017

1 reference

title

Zoledronic acid: past, present and future roles in cancer treatment (English)

1 reference

14 August 2017

1 reference

1

Fred Saad

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 April 2005

1 reference

14 August 2017

1 reference

14 August 2017

volume

1

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

149-159

1 reference

14 August 2017

cites work

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.149

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.149

Malignant bone pain: pathophysiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.149

Overview of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.149

Development of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.149

Structure-activity relationships of various bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.149

Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.149

Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.149

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.149

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.149

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.149

Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.149

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.149

Molecular mechanisms of action of bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.149

Protein prenylation: molecular mechanisms and functional consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.149

Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.149

Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.149

Bisphosphonates: a review of their pharmacokinetic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.149

A dose-finding study of zoledronate in hypercalcemic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.149

A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.149

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.149

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.149

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.149

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.149

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.149

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.149

Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.149

Cox's Regression Model for Counting Processes: A Large Sample Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14796694.1.2.149

21 January 2018

Identifiers

DOI

10.1517/14796694.1.2.149

1 reference

14 August 2017

1 reference